Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05186233 · ClinicalTrials.gov registry record · NA
Use of Consumer Sleep Technology to Treat Shift Work Disorder
A NA study of Shift-work Disorder, sponsored by Henry Ford Health System.
- Completed
- Registry status
- NA
- Development phase
- 63
- Enrollment target
- 1
- Study location
NCT05186233: Completed NA study of Shift-work Disorder, sponsored by Henry Ford Health System.
NCT05186233 is a NA study of Shift-work Disorder that has completed, run by Henry Ford Health System. The registered enrollment target is 63 participants, below the 237-participant average among 3 other Shift-work Disorder trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05186233, a NA study of Shift-work Disorder, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- NA
- Development phase
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the effectiveness of a personalized light exposure schedule for Shift Work Disorder (SWD) in night shift workers compared to a non-personalized light exposure schedule.
Primary Outcome
Melatonin values will be measured in saliva samples, collected in dim light conditions in a laboratory, to determine circadian phase.
Conditions Studied
Interventions
- BEHAVIORAL Phototherapy
Study Locations (1)
Michigan
- Henry Ford Columbus Medical Center - Novi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2022-04-18 |
| Est. Completion | 2025-03-31 |
| Phase | NA |
What the finished NCT05186233 record still lists
NCT05186233 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 237-participant average among 3 other Shift-work Disorder trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Shift-work Disorder appearing as the primary indexed condition, and to 1 intervention - of which Phototherapy is the first listed.
NCT05186233 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT05186233 about?
NCT05186233 is a clinical study titled "Use of Consumer Sleep Technology to Treat Shift Work Disorder". The purpose of this study is to examine the effectiveness of a personalized light exposure schedule for Shift Work Disorder (SWD) in night shift workers compared to a non-personalized light exposure schedule.
What is the current status of trial NCT05186233?
This trial is currently completed. It is a NA study. The enrollment target is 63 participants. The study started on 2022-04-18. Estimated completion is 2025-03-31.
What conditions does trial NCT05186233 study?
This clinical trial studies the following conditions: Shift-work Disorder.
What interventions are being tested in trial NCT05186233?
The interventions under investigation include: Phototherapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT05186233?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05186233 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Shift-work Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI